Skip to main content
. 2023 Mar 22;11(3):e006262. doi: 10.1136/jitc-2022-006262

Table 3.

Toxicity (TOX) events and clinical outcomes

Outcome Arm A: Daratumumab
(n=15)
Arm B: Edicotinib
(n=10)
TOX
 Patients with any TOX event 2 (13%) 2 (20%)
 Surgery delay 0 (0%) 0 (0%)
 Surgical complications 0 (0%) 1 (10%)
 Grade 3 infusion reactions >6 hours 0 (0%) NA
 Related grade 2 lasting >14 days 1 (7%)—infection 1 (10%)—lymphocyte count decrease
 Related grade 3, not excepted 1 (7%)—urticaria 0 (0%)
pCR
 pCR empirical estimate N (%) 0 (0%) 0 (0%)

pCR, pathologic complete remission.